Inactief instrument

Andere talen Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Aandelen

IL0006290147

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03/05
Teva to Present at the 2024 Bank of America Healthcare Conference	03/05
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02/05
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30/04
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22/04
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Teva CEO over tweede kwartaal, mogelijke schikking met DOJ

02 augustus 2023 om 21:19 uur